Market Overview

UPDATE: Bank of America Initiates Coverage on MacroGenics on Multiple Immunotherapy Platforms


In a report published Monday, Bank of America analyst Steve Byrne initiated coverage on MacroGenics (NASDAQ: MGNX) with a Neutral rating and $30.00 price target.

In the report, Bank of America noted, “We are initiating coverage of MacroGenics (MGNX), a clinical stage oncology focused biopharmaceutical company with a $30 PO and Neutral rating. We believe MGNX' three immunotherapy platforms have meaningful potential, based primarily on pre-clinical data. The lead asset margetuximab is a modified version of Herceptin with increased binding affinity to cell-killing macrophages. MGA271 is another tumor targeting antibody that could block cancer-caused T-cell inhibition (same receptor family as PD1). MGNX also has a bi-functional antibody technology called DART, which could offer significant advantages vs. conventional antibodies (e.g. simultaneous binding to tumor and T-cells). Our DCF-derived PO of $30 is driven primarily by margetuximab. We could see upside post data read-outs in 2014.”

MacroGenics closed on Friday at $27.32.

Latest Ratings for MGNX

Nov 2020Morgan StanleyMaintainsUnderweight
Nov 2020SVB LeerinkMaintainsOutperform
Oct 2020Morgan StanleyMaintainsUnderweight

View More Analyst Ratings for MGNX
View the Latest Analyst Ratings


Related Articles (MGNX)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Initiation Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at